Compare American Well Corp (AMWL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs BioNano Genomics Inc — how do they compare? American Well Corp trades at $13.01 (market cap $220.94M), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: American Well Corp is far larger — about 16.2× BioNano Genomics Inc's market cap, and American Well Corp is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| AMWL | BNGO | |
|---|---|---|
Market Cap | $220.94M | $13.66M |
Sector | Health | Health |
52-Week High | $13.58 | $4.92 |
52-Week Low | $3.78 | $1.06 |
Enterprise Value | $27.98M | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $12.54, down 7.66% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows improving financial trends, with revenue declining to $249.33M in 2025 but net losses narrowing significantly to -$95.70M. Recent Q2 2026 earnings beat expectations, and news highlights strategic developments including a key executive appointment at Amazon's healthcare unit.
The outlook suggests cautious optimism as AMWL progresses toward cash-flow breakeven, supported by analyst coverage leaning Hold. Key risks include persistent revenue declines and high cash burn, though improving margins and reduced losses indicate potential for recovery if execution continues.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
